Cargando…
Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab
Delanzomib is a novel proteasome inhibitor initially developed for treating multiple myeloma. It was found to inhibit the expression of tumor necrosis factor alpha (TNF-α). This study aimed to investigate the ameliorating effect of delanzomib on collagen-induced arthritis (CIA) and to explore the ph...
Autores principales: | Wang, Lei, Liu, Lixiong, Hong, Xiaoping, Liu, Dongzhou, Cheng, Zeneng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645831/ https://www.ncbi.nlm.nih.gov/pubmed/34880764 http://dx.doi.org/10.3389/fphar.2021.782385 |
Ejemplares similares
-
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
por: Zamora-Atenza, Carlos, et al.
Publicado: (2014) -
Adalimumab in the treatment of arthritis
por: Mease, Philip J
Publicado: (2007) -
Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study
por: D'Angelo, Salvatore, et al.
Publicado: (2019) -
The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet’s Retinal Vasculitis
por: Yang, Shizhao, et al.
Publicado: (2021) -
Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis
por: Wang, Mopei, et al.
Publicado: (2019)